Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (87) 87
humans (86) 86
female (63) 63
male (63) 63
endocrinology & metabolism (54) 54
middle aged (54) 54
adult (53) 53
aged (36) 36
diabetes (36) 36
insulin (28) 28
life sciences (21) 21
treatment outcome (21) 21
care and treatment (20) 20
hypoglycemic agents - administration & dosage (20) 20
research (18) 18
type 2 diabetes (18) 18
blood glucose - analysis (16) 16
diabetes mellitus, type 1 - drug therapy (16) 16
diabetes mellitus, type 1 - blood (15) 15
drug administration schedule (15) 15
hypoglycemia (15) 15
abridged index medicus (14) 14
adolescent (14) 14
aged, 80 and over (14) 14
blood glucose - metabolism (14) 14
diabetes mellitus, type 2 - drug therapy (14) 14
hypoglycemic agents - therapeutic use (14) 14
insulin - administration & dosage (14) 14
mellitus (14) 14
therapy (14) 14
diabetes mellitus, type 2 - blood (13) 13
glycemic control (13) 13
hematology (13) 13
risk factors (13) 13
time factors (13) 13
clinical trials (12) 12
glucose (12) 12
internal medicine (12) 12
management (12) 12
patients (12) 12
type 1 diabetes (12) 12
glycated hemoglobin a - metabolism (11) 11
human health and pathology (11) 11
original articles (11) 11
usage (11) 11
young adult (11) 11
analysis (10) 10
cancer (10) 10
child (10) 10
diabetes mellitus (10) 10
glycated hemoglobin a - analysis (10) 10
insulin - therapeutic use (10) 10
insulin infusion systems (10) 10
original research (10) 10
blood glucose - drug effects (9) 9
body mass index (9) 9
clinical medicine (9) 9
diabetes therapy (9) 9
exenatide (9) 9
medicine, general & internal (9) 9
oncology (9) 9
prospective studies (9) 9
dose-response relationship, drug (8) 8
drug therapy (8) 8
drug therapy, combination (8) 8
hyperglycemia (8) 8
chronic myelogenous leukemia (7) 7
disease management (7) 7
efficacy (7) 7
follow-up studies (7) 7
infusion (7) 7
medicine & public health (7) 7
patient outcomes (7) 7
postprandial period (7) 7
risk (7) 7
survival (7) 7
trial (7) 7
type 2 diabetes mellitus (7) 7
animals (6) 6
basal insulin (6) 6
blood sugar (6) 6
blood-glucose (6) 6
follow-up (6) 6
france (6) 6
france - epidemiology (6) 6
glycosylated hemoglobin (6) 6
hypoglycemic agents - adverse effects (6) 6
insulin pumps (6) 6
leukemia (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6) 6
medical research (6) 6
medicine, experimental (6) 6
metabolism (6) 6
multicenter (6) 6
mutation (6) 6
original (6) 6
peptides - administration & dosage (6) 6
recurrence (6) 6
safety (6) 6
adults (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
by Bougouin, Wulfran and Marijon, Eloi and Planquette, Benjamin and Karam, Nicole and Dumas, Florence and Celermajer, David and Jost, Daniel and Lamhaut, Lionel and Beganton, Frankie and Cariou, Alain and Meyer, Guy and Jouven, Xavier and Bureau, Côme and Charpentier, Julien and Salem, Omar Ben Hadj and Guillemet, Lucie and Arnaout, Michel and Ferre, Alexis and Geri, Guillaume and Mongardon, Nicolas and Pène, Frédéric and Chiche, Jean-Daniel and Mira, Jean-Paul and Labro, Guylaine and Belon, François and Luu, Vinh-Phuc and Chenet, Julien and Besch, Guillaume and Puyraveau, Marc and Piton, Gaël and Capellier, Gilles and Martin, Maëlle and Lascarrou, Jean-Baptiste and Le Thuaut, Aurélie and Lacherade, Jean-Claude and Martin-Lefèvre, Laurent and Fiancette, Maud and Vinatier, Isabelle and Lebert, Christine and Bachoumas, Konstantinos and Yehia, Aihem and Henry-Laguarrigue, Matthieu and Colin, Gwenhaël and Reignier, Jean and Privat, Elodie and Escutnaire, Joséphine and Dumont, Cyrielle and Baert, Valentine and Vilhelm, Christian and Hubert, Hervé and Robert-Edan, Vincent and Lakhal, Karim and Quartin, Andrew and Hobbs, Brian and Cely, Cynthia and Bell, Cynthia and Pham, Tai and Schein, Roland and Geng, Yimin and Ng, Chaan and Ehrmann, Stephan and Gandonnière, Charlotte Salmon and Boisramé-Helms, Julie and Le Tilly, Olivier and De Bretagne, Isabelle Benz and Mercier, Emmanuelle and Mankikian, Julie and Bretagnol, Anne and Meziani, Ferhat and Halimi, Jean Michel and Le Guellec, Chantal Barin and Gaudry, Stéphane and Hajage, David and Tubach, Florence and Pons, Bertrand and Boulet, Eric and Boyer, Alexandre and Chevrel, Guillaume and Lerolle, Nicolas and Carpentier, Dorothée and de Prost, Nicolas and Lautrette, Alexandre and Mayaux, Julien and Nseir, Saad and Ricard, Jean-Damien and Dreyfuss, Didier and Robert, René and Garzotto, Franscesco and Kipnis, Eric and Tetta, Ciro and Ronco, Claudio and Schnell, David and Aurelie, Bourmaud and Reynaud, Marie and Clec’h, Christophe and Benyamina, Mourad and Vincent, François and Mariat, Christophe and Bornstain, Caroline and Rouleau, Stephane and ... and ENCEPHALITICA Study Group and GFRUP RMEF and for the EurêClark Study Group and REVA ECMOnet and REA-RAISIN Study Group and Sudden Death Expertise Center and for the HYPER2S Investigators and REVA Research Network and for the Purpura Fulminans Study Group and DO-RE-MI-FA Group and AKIKI Study Group and Groupe Communication et Simulation en Pédiatrie
Annals of Intensive Care, ISSN 2110-5820, 1/2017, Volume 7, Issue S1, pp. 1 - 104
Intensive / Critical Care Medicine | Emergency Medicine | Anesthesiology | Medicine & Public Health
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. L'Albero della rivoluzione
: le interpretazioni della Rivoluzione francese
by Bongiovanni, Bruno, 1947 and Guerci, Luciano
1989, Saggi, ISBN 8806115626, Volume 722, xxiv, 687 p., [16] p. of plates
Biography | France HistoryHistoriography | Historians | Literature and history | Literature and revolutions
Book
Details down arrow
3. Full Text Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
by Mahon, François-Xavier, Prof and Réa, Delphine, MD and Guilhot, Joëlle, PhD and Guilhot, François, Prof and Huguet, Françoise, MD and Nicolini, Franck, MD and Legros, Laurence, MD and Charbonnier, Aude, MD and Guerci, Agnès, MD and Varet, Bruno, Prof and Etienne, Gabriel, MD and Reiffers, Josy, Prof and Rousselot, Philippe, Prof and FILMC and Intergroupe Français des Leucémies Myéloïdes Chroniques
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Summary Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | RESPONSES | INTERFERON-ALPHA | MESYLATE DISCONTINUATION | THERAPY | CML | ONCOLOGY | COMPLETE CYTOGENETIC REMISSION | FOLLOW-UP | CYTARABINE | STEM-CELL TRANSPLANTATION | Piperazines - administration & dosage | Recurrence | Prospective Studies | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Benzamides | Antimitotic agents | Arson | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Long‐term follow‐up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients
by Adès, Lionel and Chevret, Sylvie and Raffoux, Emmanuel and Guerci‐Bresler, Agnes and Pigneux, Arnaud and Vey, Nobert and Lamy, Thierry and Huguet, Francoise and Vekhoff, Anne and Lambert, Jean‐Francois and Lioure, Bruno and Botton, Stephane and Deconinck, Erick and Ferrant, Augustin and Thomas, Xavier and Quesnel, Bruno and Cassinat, Bruno and Chomienne, Christine and Dombret, Hervé and Degos, Laurent and Fenaux, Pierre and European APL Grp and European APL group
American Journal of Hematology, ISSN 0361-8609, 07/2013, Volume 88, Issue 7, pp. 556 - 559
All-trans retinoic acid (ATRA) combined to anthracycline-based chemotherapy is the reference treatment of acute promyelocytic leukemia (APL). Whereas, in... 
SURVIVAL | MAINTENANCE | CONSOLIDATION | THERAPY | COMPETING RISK | ANTHRACYCLINE | TRANS-RETINOIC ACID | HEMATOLOGY | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | ARSENIC TRIOXIDE | Recurrence | Tretinoin - administration & dosage | Leukemia, Promyelocytic, Acute - pathology | Follow-Up Studies | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols | Male | Treatment Outcome | Cytarabine - administration & dosage | Early Termination of Clinical Trials | Female | Daunorubicin - administration & dosage | Leukemia, Promyelocytic, Acute - drug therapy | Evaluation | Care and treatment | Chemotherapy | Daunorubicin | Leukemia | Clinical trials | Tretinoin | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)
by Nauck, Michael and Weinstock, Ruth S and Umpierrez, Guillermo E and Guerci, Bruno and Skrivanek, Zachary and Milicevic, Zvonko
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
by Gallwitz, Baptist, Prof and Guzman, Juan, MD and Dotta, Francesco, MD and Guerci, Bruno, MD and Simó, Rafael, MD and Basson, Bruce R, MSc and Festa, Andreas, MD and Kiljański, Jacek, MD and Sapin, Hélène, MSc and Trautmann, Michael, MD and Schernthaner, Guntram, Prof
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9833, pp. 2270 - 2278
Summary Background Glycaemic control deteriorates progressively over time in patients with type 2 diabetes. Options for treatment escalation remain... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MONOTHERAPY | MANAGEMENT | EFFICACY | LIRAGLUTIDE | SAFETY | PARALLEL-GROUP | ROSIGLITAZONE | INSULIN SENSITIVITY | VS. GLIMEPIRIDE | BETA-CELL FUNCTION | Metformin - therapeutic use | Drug Administration Schedule | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Risk Factors | Diabetes Mellitus, Type 2 - prevention & control | Male | Peptides - administration & dosage | Young Adult | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Hypoglycemic Agents - administration & dosage | Treatment Failure | Adolescent | Aged, 80 and over | Venoms - administration & dosage | Adult | Female | Aged | Sulfonylurea Compounds - administration & dosage | Blood Glucose - metabolism | Glimepiride | Control | Usage | Research | Blood sugar | Exenatide | Automation | Gastrointestinal diseases | Blood pressure | Diabetes | Clinical medicine | Glucose | Pharmaceutical industry | Insulin | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
by Etienne, Gabriel and Guilhot, Joëlle and Rea, Delphine and Rigal-Huguet, Françoise and Nicolini, Franck and Charbonnier, Aude and Guerci-Bresler, Agnès and Legros, Laurence and Varet, Bruno and Gardembas, Martine and Dubruille, Viviane and Tulliez, Michel and Noel, Marie-Pierre and Ianotto, Jean-Christophe and Villemagne, Bruno and Carré, Martin and Guilhot, François and Rousselot, Philippe and Mahon, François-Xavier
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for... 
CHRONIC MYELOGENOUS LEUKEMIA | TRIAL | MESYLATE DISCONTINUATION | THERAPY | ONCOLOGY | COMPLETE MOLECULAR REMISSION | PATIENTS RECEIVING IMATINIB | DASATINIB | CML PATIENTS | NILOTINIB | CESSATION | Predictive Value of Tests | Recurrence | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Patient Selection | Neoplasm, Residual | Molecular Diagnostic Techniques | Time Factors | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Aged | Biomarkers, Tumor - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial
by Rosenstock, Julio and Guerci, Bruno and Hanefeld, Markolf and Gentile, Sandro and Aronson, Ronnie and Tinahones, Francisco J and Roy-Duval, Christine and Souhami, Elisabeth and Wardecki, Marek and Ye, Jenny and Perfetti, Riccardo and Heller, Simon and GetGoal Duo-2 Trial Investigators
Diabetes Care, ISSN 0149-5992, 08/2016, Volume 39, Issue 8, pp. 1318 - 1328
OBJECTIVETo provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type... 
GLYCEMIC CONTROL | RAPID-ACTING INSULIN | HYPERGLYCEMIA | MANAGEMENT | LIRAGLUTIDE | PATIENT-CENTERED APPROACH | ENDOCRINOLOGY & METABOLISM | MODALITIES | MELLITUS | RECEPTOR AGONIST | GLUCAGON | Body Mass Index | Overweight - complications | Body Weight | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Endpoint Determination | Postprandial Period | Female | Aged | Metformin - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Meals | Glucagon-Like Peptide-1 Receptor - agonists | Type 2 diabetes | Overweight persons | Complications and side effects | Mouthwashes | Dosage and administration | Health aspects | Risk factors | Obesity | Diabetes | Peptides | Hypoglycemia | Insulin | Optimization | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The realtrend study
by Raccah, Denis and Sulmont, Véronique and Reznik, Yves and Guerci, Bruno and Renard, Eric and Hanaire, Hélène and Jeandidier, Nathalie and Nicolino, Marc
Diabetes Care, ISSN 0149-5992, 12/2009, Volume 32, Issue 12, pp. 2245 - 2250
OBJECTIVE - To compare the improvements in glycemic control associated with transitioning to insulin pump therapy in patients using continuous glucose... 
MULTIPLE DAILY INJECTIONS | SUBCUTANEOUS INSULIN INFUSION | YOUTH | GLYCEMIC CONTROL | BLOOD-GLUCOSE | ENDOCRINOLOGY & METABOLISM | Body Mass Index | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Monitoring, Ambulatory - methods | Glycated Hemoglobin A - metabolism | Humans | Insulin - administration & dosage | Male | Diabetes Mellitus, Type 1 - drug therapy | Dose-Response Relationship, Drug | Blood Glucose Self-Monitoring - methods | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 1 - blood | Adolescent | Age of Onset | Adult | Female | Insulin Infusion Systems | Blood Glucose - metabolism | Child | Insulin - therapeutic use | Medical research | Care and treatment | Blood sugar monitoring | Blood sugar | Patient monitoring equipment | Medicine, Experimental | Diabetes | Research | Sensors | Insulin | Diabetes therapy | Glucose | Disease management | Patients | Monitoring systems | Index Medicus | Life Sciences | Human health and pathology | Endocrinology and metabolism | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
by Philippe Rousselot and Aude Charbonnier and Pascale Cony-Makhoul and Philippe Agape and Franck E. Nicolini and Bruno Varet and Martine Gardembas and Gabriel Etienne and Delphine Réa and Lydia Roy and Martine Escoffre-Barbe and Agnès Guerci-Bresler and Michel Tulliez and Stéphane Prost and Marc Spentchian and Jean Michel Cayuela and Josy Reiffers and Jean Claude Chomel and Ali Turhan and Joëlle Guilhot and François Guilhot and François-Xavier Mahon
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Purpose More than half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) in complete molecular response (CMR) experience molecular relapse... 
MESYLATE DISCONTINUATION | ONCOLOGY | COMPLETE CYTOGENETIC REMISSION | CHRONIC MYELOID-LEUKEMIA | CESSATION | Piperazines - administration & dosage | Recurrence | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | France | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Pyrimidines - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
by Dandona, Paresh and Mathieu, Chantal and Phillip, Moshe and Hansen, Lars and Griffen, Steven C and Tschöpe, Diethelm and Thorén, Fredrik and Xu, John and Langkilde, Anna Maria and Proietto, Joseph and Stranks, Stephen and Chen, Roger and O'Neal, David and Pape, Alexia and Forbes, Mark and Morbey, Claire and Luger, Anton and Hanusch, Ursula and Schnack, Christoph and Fliesser-Goerzer, Evelyn and Hoelzl, Bertram and Ebenbichler, Christoph and Prager, Rudolf and Van Gaal, Luc and Vercammen, Chris and Scheen, Andre and Duyck, Francis and Nobels, Frank and Ruige, Johannes and Aggarwal, Naresh and Woo, Vincent and St-Pierre, Bruno and Dumas, Richard and Hramiak, Irene and Elliott, Thomas and Krarup Hansen, Troels and Henriksen, Jan Erik and Gram, Jeppe and Lihn, Aina and Bruun, Jens and Saltevo, Juha and Taurio, Jyrki and Strand, Jorma and Valle, Timo and Nieminen, Sakari and Pietilainen, Kirsi and Guerci, Bruno and Hadjadj, Samy and Cariou, Bertrand and Verges, Bruno and Borot, Sophie and Penfornis, Alfred and Schaum, Thomas and Tschoepe, Diethelm and Marck, Cornelia and Horacek, Thomas and Rose, Ludger and Klausmann, Gerhard and Luedemann, Joerg and Appelt, Steffi and Aigner, Ulrich and Goebel, Rolf and Behnke, Thomas and Ziegler, Anette-Gabriele and Peterfai, Eva and Kerenyi, Zsuzsanna and Oroszlan, Tamas and Kiss, Gyula G and Konyves, Laszlo and Piros, Gyorgyi and Mosenzon, Ofri and Shehadeh, Naim and Adawi, Faiad and Wainstein, Julio and Dotta, Francesco and Piatti, Piermarco and Genovese, Stefano and Consoli, Agostino and Di Bartolo, Paolo and Mannucci, Edoardo and Giordano, Carla and Lapolla, Annunziata and Aguilar, Carlos and Esteban, Alberto and Ruiz, Bazzoni and Ramirez, Guillermo Mondragon and Pelayo Orozco, Emilia and Alejandro, Carlos and de Alba, Stobschinski and Medina Pech, Carlos and Garza Ruiz, Jose and Sauque Reyna, Leobardo and Llamas Esperon, Guillermo and Nevarez Ruiz, Luis Alejandro and Vidrio Velazquez, Maricela and Flores Lozano, Fernando and Gonzalez Gonzalez, Jose Gerardo and Garcia-Hernandez, Pedro Alberto and Araujo-Silva, Roberto and Villeda - Espinosa, Efrain and ... and DEPICT-1 Investigators
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 11/2017, Volume 5, Issue 11, pp. 864 - 876
Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of... 
MORTALITY | OBESITY | METAANALYSIS | LIRAGLUTIDE | INSULIN-TREATMENT | SGLT2 INHIBITORS | GLUCOSE | ENDOCRINOLOGY & METABOLISM | MELLITUS | KIDNEY | ASSOCIATION | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Humans | Middle Aged | Body Weight - drug effects | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - drug therapy | Adult | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Insulin - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
by Diamant, M and Van Gaal, L and Stranks, S and Guerci, B and MacConell, L and Haber, H and Scism-Bacon, J and Trautmann, M
Diabetes Care, ISSN 0149-5992, 2012, Volume 35, Issue 4, pp. 683 - 689
OBJECTIVE - We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive... 
TRIAL | METFORMIN | GLYCEMIC CONTROL | SULFONYLUREA | THERAPY | EXENDIN-4 | INITIATION | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TREATED PATIENTS | WEIGHT | Follow-Up Studies | Humans | Diabetes Mellitus, Type 2 - metabolism | Peptides - administration & dosage | Dose-Response Relationship, Drug | Drug Dosage Calculations | Hypoglycemic Agents - administration & dosage | Time Factors | Venoms - administration & dosage | Cardiovascular Physiological Phenomena - drug effects | Blood Glucose - analysis | Drug Administration Schedule | Venoms - adverse effects | Treatment Outcome | Insulin, Long-Acting - adverse effects | Diabetes Mellitus, Type 2 - blood | Algorithms | Diabetes Mellitus, Type 2 - physiopathology | Insulin, Long-Acting - administration & dosage | Insulin Glargine | Titrimetry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Weight loss | Medicine, Experimental | Hypoglycemic agents | Research | Diabetes | Clinical trials | Insulin resistance | Consciousness | Insulin | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
by Diamant, Michaela, Prof and Van Gaal, Luc, Prof and Guerci, Bruno, Prof and Stranks, Stephen, MD and Han, Jenny, MS and Malloy, Jaret, PhD and Boardman, Marilyn K, PharmD and Trautmann, Michael E, Dr
Lancet Diabetes & Endocrinology, The, ISSN 2213-8587, 2014, Volume 2, Issue 6, pp. 464 - 473
Summary Background When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1)... 
Endocrinology & Metabolism | Other | METFORMIN | 26-WEEK | PIOGLITAZONE | SULFONYLUREA | THERAPY | EFFICACY | SAFETY | BASAL INSULIN | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ACHIEVE GLYCEMIC CONTROL | Body Mass Index | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Treatment Outcome | Diabetes Mellitus, Type 2 - epidemiology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide 1 - agonists | Insulin Glargine | Injections, Subcutaneous | Insulin, Long-Acting - therapeutic use | Taiwan | Venoms - therapeutic use | Female | Diabetes Mellitus, Type 2 - drug therapy | Peptides - therapeutic use | Republic of Korea | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights